KOZARICH JOHN W 4

What Happened

• John W. Kozarich, a Director of Ligand Pharmaceuticals (LGND), sold a total of 467 shares in open-market transactions on February 2, 2026, for aggregate proceeds of approximately $91,489.
• Individual reported disposals: 39 shares @ $191.00 ($7,449); 1 share @ $192.18 ($192); 23 shares @ $195.60 ($4,499); 381 shares @ $196.36 ($74,814); and 23 shares @ $197.19 ($4,535). This activity is a sale (not a purchase) and is commonly considered routine insider selling.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (timely within reporting window).
• Total sold: 467 shares for ~ $91,489 total proceeds.
• Shares owned after the transaction: not specified in the filing.
• Notable footnotes:
  • F1: Trades were made pursuant to a written Rule 10b5-1 trading plan adopted March 7, 2025.
  • F2: The $196.36 weighted-average price line reflects multiple sales at prices ranging $196.01–$196.84; the reporting person will provide a breakdown on request.
• Filing not indicated as late.

Context

• This report documents straight open-market sales by a board member under a pre-established 10b5-1 plan; such sales are typically routine and do not, by themselves, indicate the insider’s view on the company's prospects.
• No options were exercised, no gifts or awards were reported, and no additional derivative transactions are noted in this filing.